IL-22+ CD4+ T Cells Are Associated with Therapeutic Trichuris trichiura Infection in an Ulcerative Colitis Patient

@article{Broadhurst2010IL22CT,
  title={IL-22+ CD4+ T Cells Are Associated with Therapeutic Trichuris trichiura Infection in an Ulcerative Colitis Patient},
  author={Mara Jana Broadhurst and Jacqueline M. Leung and Vikram S. Kashyap and Joseph M. McCune and Uma Mahadevan and James H. McKerrow and P’ng Loke},
  journal={Science Translational Medicine},
  year={2010},
  volume={2},
  pages={60ra88 - 60ra88},
  url={https://api.semanticscholar.org/CorpusID:27792133}
}
A comprehensive cellular and molecular portrait of dynamic changes in the intestinal mucosa of an individual who infected himself with Trichuris trichiura to treat his symptoms of ulcerative colitis is provided.
View on AAAS
ncbi.nlm.nih.gov
200 Citations
Highly Influential Citations
11
Background Citations
66
Methods Citations
3
Results Citations
3

200 Citations

Mucosal and systemic immune modulation by Trichuris trichiura in a self‐infected individual

It is confirmed that helminths modulate regional and systemic human immunity by observing several indicators of modulation of systemic immunity during the T. trichiura infection.

Excretory/Secretory Products from Trichinella spiralis Adult Worms Ameliorate DSS-Induced Colitis in Mice

Mice treated with AES significantly ameliorated the severity of the DSS-induced colitis indicated by the reduced disease manifestations, improved macroscopic and microscopic inflammation correlated with the up-regulation of Treg response and down- regulation of pro-inflammatory cytokines in the spleens, MLN and colon of treated mice.

Where are we on worms?

Evidence is accumulating that highly hygienic living conditions create risk for developing immune-mediated disease such as IBD.

Therapeutic Helminth Infection of Macaques with Idiopathic Chronic Diarrhea Alters the Inflammatory Signature and Mucosal Microbiota of the Colon

It is suggested that helminth treatment in primates can ameliorate colitis by restoring mucosal barrier functions and reducing overall bacterial attachment, and also by altering the communities of attached bacteria.

Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis

It is speculated that if the data from animal models translate to humans, noting the heterogeneity therein, then the choice between use of viable helminth ova, helmineth extracts/molecules or antigen-pulsed immune cells could be matched to disease management in defined cohorts of patients with inflammatory bowel disease.

IL-22 Mediates Goblet Cell Hyperplasia and Worm Expulsion in Intestinal Helminth Infection

Ex vivo and in vitro analysis demonstrated that IL-22 is able to directly induce the expression of several goblet cell markers, including mucins, and thus, a key role in anti-helminth immunity is revealed.

Helminth therapy or elimination: epidemiological, immunological, and clinical considerations.

Potential of human helminth therapy for resolution of inflammatory bowel disease: The future ahead.

Helminths in alternative therapeutics of inflammatory bowel disease

This review article summarizes the potential of helminth therapy as an alternative therapeutic or an adjuvant to the existing therapeutic procedures for IBD treatment.

Exclusive dependence of IL-10Rα signalling on intestinal microbiota homeostasis and control of whipworm infection

The findings emphasize the pivotal role of systemic IL-10Rα signalling on immune cells in promoting microbiota homeostasis and maintaining the intestinal epithelial barrier, thus preventing immunopathology during whipworms infections.
...

49 References

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.

Ova therapy seems safe and effective in patients with active colitis, and improvement according to the intent-to-treat principle occurred in 13 of 30 patients with ova treatment compared with 4 of 24 patients given placebo.

Intestinal epithelial cell secretion of RELM-β protects against gastrointestinal worm infection

A novel mechanism for host protection at the mucosal interface is demonstrated that explains how stimulation of epithelial cells by IL-4 and IL-13 contributes to protection against parasitic helminthes that dwell in the intestinal lumen.

Vomiting in the recently anticoagulated patient

These findings also support the premise that natural exposure to helminths such as T suis affords protection from immunological diseases like Crohn’s disease.

Helminths as governors of immune-mediated inflammation.

THE ROLE OF IL-13 AND NK T CELLS IN EXPERIMENTAL AND HUMAN ULCERATIVE COLITIS

In the following review the insights gained from both animal models and human studies as to the function that IL-13 and NK T cells have in the pathogenesis of UC will be discussed.

RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract.

It is demonstrated that a recently described intestinal goblet cell-specific protein, RELMbeta/FIZZ2, is induced after exposure to three phylogenetically distinct GI nematode pathogens, and it is suggested that intestinal goblingen cell-derived RELM beta may be a novel Th2 cytokine-induced immune-effector molecule in resistance to GI nem atode infection.

Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.

BACKGROUND & AIMS Inflammatory bowel diseases (IBDs) and the irritable bowel syndrome (IBS) are heterogeneous disorders of the gastrointestinal tract and can profoundly affect the quality of life.…

How much human helminthiasis is there in the world?

This article has sought to place Stoll's evaluation of human helminthiasis in a contemporary setting and to address some of the questions he asked and to review aspects of current progress in the control ofhuman helminthsiasis.

IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.

A novel microinjection-based local gene-delivery system that is capable of targeting the inflamed intestine and demonstrating a therapeutic potency for IL-22-mediated activation of the innate immune pathway in a mouse model of Th2-mediated colitis that induces disease with characteristics similar to that of IBD ulcerative colitis is developed.

A review of infliximab use in ulcerative colitis.